Summit Therapeutics opens a global Phase II study of ivonescimab-based regimens for advanced clear cell renal cell carcinoma
MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.
MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.